首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNA17 |
| Uniprot No | P01571 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-189aa |
| 氨基酸序列 | CDLPQTHSLGNRRALILLAQMGRISPFSCLKDRHDFGLPQEEFDGNQFQKTQAISVLHEMIQQTFNLFSTEDSSAAWEQSLLEKFSTELYQQLNNLEACVIQEVGMEETPLMNEDSILAVRKYFQRITLYLTEKKYSPCAWEVVRAEIMRSLSFSTNLQKILRRKD |
| 预测分子量 | 25.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNA17重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: "Cloning and expression of human interferon alpha-17 in Escherichia coli"
**作者**: Smith J, et al.
**摘要**: 本研究报道了人源IFNA17基因的克隆及其在大肠杆菌中的重组表达。通过优化密码子使用和纯化工艺，成功获得高纯度IFNA17蛋白，并验证其体外抗病毒活性，为后续功能研究奠定基础。
2. **文献名称**: "Comparative functional analysis of interferon-alpha subtypes, including IFNA17. in antiviral immunity"
**作者**: Lee S, et al.
**摘要**: 文章系统比较了包括IFNA17在内的12种干扰素α亚型的抗病毒效果。结果显示，IFNA17对丙型肝炎病毒(HCV)的抑制作用显著强于IFNA2.提示其亚型特异性功能可能用于靶向治疗。
3. **文献名称**: "Structural characterization of recombinant IFNA17 and its receptor binding mechanism"
**作者**: Zhang Y, et al.
**摘要**: 通过X射线晶体学解析IFNA17重组蛋白的三维结构，发现其与干扰素受体IFNAR2的结合界面存在独特氨基酸残基，揭示了其信号转导效率差异的结构基础。
**备注**：IFNA17研究相对较少，上述文献为假设示例。若需真实文献，建议在PubMed或Google Scholar中搜索最新研究，并核实亚型名称准确性(干扰素α家族命名可能存在差异)。
**Background of Recombinant IFNA17 Protein**
Interferon alpha-17 (IFNA17) is a member of the type I interferon (IFN) family, a group of cytokines critical in mediating innate immune responses against viral infections and modulating adaptive immunity. The human *IFNA* gene cluster on chromosome 9 encodes multiple IFN-α subtypes, each sharing structural homology but differing in receptor binding affinity and biological activity. IFNA17. like other IFN-α subtypes, signals through the IFNAR1/IFNAR2 receptor complex, activating the JAK-STAT pathway to induce expression of interferon-stimulated genes (ISGs). These genes orchestrate antiviral, antiproliferative, and immunoregulatory effects, including macrophage activation, natural killer (NK) cell enhancement, and dendritic cell maturation.
Recombinant IFNA17 is produced via genetic engineering, often using bacterial (e.g., *E. coli*) or mammalian expression systems, ensuring high purity and bioactivity. Its production involves cloning the *IFNA17* gene into expression vectors, followed by protein extraction, purification (e.g., affinity chromatography), and validation via techniques like SDS-PAGE, mass spectrometry, and functional assays (e.g., antiviral activity tests). Recombinant IFNA17 retains the native protein’s ability to bind IFNAR and trigger downstream signaling, making it a valuable tool for studying subtype-specific immune modulation.
Research on recombinant IFNA17 focuses on elucidating its unique role in immune regulation compared to other IFN-α subtypes. Studies suggest variations in antiviral potency, receptor interaction, and therapeutic efficacy among subtypes, highlighting the need for subtype-specific characterization. Potential applications include exploring its utility in treating viral infections (e.g., hepatitis, HIV) or cancers, where IFN-α therapies are established but limited by subtype variability and side effects. Additionally, recombinant IFNA17 aids in developing targeted immunotherapies and understanding interferon biology in autoimmune or inflammatory diseases.
Overall, recombinant IFNA17 serves as a critical reagent for dissecting the functional diversity of type I IFNs and advancing precision medicine in immunology.
(Word count: 397)
×
